Neuren Pharmaceuticals (ASX:NEU) is an Australian-based pharmaceutical company that develops and commercialises new drugs for the treatment of central nervous system (CNS) disorders. The company's flagship asset is NNZ-2566, a drug candidate for the treatment of Fragile X syndrome, a rare genetic disorder that causes intellectual disability. Neuren is also developing a number of other drug candidates for the treatment of other CNS disorders, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. Neuren's operations are focused on the development and commercialization of new drugs for CNS disorders. The company has a number of drug candidates in clinical trials, and is also working on the development of new preclinical drug candidates.